Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration.

Abstract

OBJECTIVE:

Assess the efficacy of intravitreal aflibercept on pigment epithelial detachments (PED) associated with previously treated patients with neovascular age-related macular degeneration (AMD).

DESIGN:

Retrospective study.

PARTICIPANTS:

Sixty eyes.

METHODS:

Patients with persistent PED who were treated with intravitreal aflibercept (2.0 mg) with ≥2 previous injections of bevacizumab (1.25 mg) or ranibizumab (0.5 mg) were analyzed.

RESULTS:

Mean number of prior injections was 24.8 during a mean of 32 months of management (range 3-77 months). Baseline mean PED height was 258 µm (range 80-687 µm), which decreased at 1, 6, and 12 months upon switching to aflibercept to 226 µm (-14%, range 34-701 µm), 215 µm (-18%, range 0-666 µm), and 208 µm (-22%, range 0-752 µm), respectively. The majority of eyes experienced a decrease in PED height after switching to aflibercept: 50/58 (86%), 38/47 (81%), and 37/47 (79%) at months 1, 6, and 12, respectively. Reduction in PED height was weakly correlated with improved visual acuity (R(2) = 0.11).

CONCLUSIONS:

Intravitreal aflibercept resulted in significant reduction in PED height in previously treated eyes with neovascular AMD.

• Authors: James C Major Jr, Charles C Wykoff, Daniel E Croft, Rui Wang, Angeline F Mariani, Anna E Lehmann, David M Brown
• Journal: Canadian journal of ophthalmology. Journal canadien d'ophtalmologie (Can J Ophthalmol) Vol. 50 Issue 5 Pg. 373-7 (Oct 2015) ISSN: 1715-3360 [Electronic] England
• PMID: 26455973 (Publication Type: Journal Article)
• Copyright: Copyright © 2015 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.

Chemical References

• Angiogenesis Inhibitors
• Recombinant Fusion Proteins
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• aflibercept
• Bevacizumab
• Receptors, Vascular Endothelial Growth Factor
• Ranibizumab

Topics

• Aged
• Aged, 80 and over
• Angiogenesis Inhibitors (therapeutic use)
• Bevacizumab (therapeutic use)
• Drug Substitution
• Female
• Humans
• Intravitreal Injections
• Male
• Middle Aged
• Ranibizumab (therapeutic use)
• Receptors, Vascular Endothelial Growth Factor (therapeutic use)
• Recombinant Fusion Proteins (therapeutic use)
• Retinal Detachment (diagnosis, drug therapy, etiology)
• Retinal Pigment Epithelium (drug effects, pathology)
• Retrospective Studies
• Tomography, Optical Coherence
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity (drug effects)
• Wet Macular Degeneration (drug therapy)